๐Ÿ† World's First Agentic AI Platform for Genomics

Decode the Genome.
Accelerate Every Cure.

12 autonomous AI agents classify genetic variants, generate zero-hallucination clinical reports, discover drug targets, and match patients to trials โ€” in real time. HIPAA compliant. Acquisition ready.

Request Live Demo Explore API Docs โ†’
12ร—
Autonomous Agents
0.937
G-ARVIS Score
100%
Zero Hallucination
<8s
Per Variant
1M+
Variants/Day
ACMG/AMP 2015 Compliant FHIR R4 + HL7 v2.x Integration Epic & Cerner Ready AWS ยท Azure ยท GCP ยท OCI ยท On-Prem ClinVar ยท gnomAD ยท OMIM ยท OncoKB ยท PharmGKB CAP/CLIA Aligned ยท HIPAA ยท GDPR VIS Score (Patent Pending) G-ARVIS Quality Framework ACMG/AMP 2015 Compliant FHIR R4 + HL7 v2.x Integration Epic & Cerner Ready AWS ยท Azure ยท GCP ยท OCI ยท On-Prem ClinVar ยท gnomAD ยท OMIM ยท OncoKB ยท PharmGKB CAP/CLIA Aligned ยท HIPAA ยท GDPR
The Problem

Genomics is Drowning in Manual Work

Clinical labs spend 70% of interpretation time on manual lookups, copy-paste, and documentation โ€” while patients wait weeks for answers.

โณ
Days of Manual Variant Interpretation
Each BRCA variant requires 4โ€“6 database lookups, manual ACMG evidence scoring, and expert sign-off โ€” taking 2โ€“5 days per report.
โš ๏ธ
Hallucination Risk in AI-Generated Reports
Existing LLM tools fabricate citations and make uncited pathogenic classifications โ€” creating patient safety liability.
๐Ÿงฉ
Fragmented Tool Ecosystem
Labs stitch together 8โ€“12 separate tools with no unified intelligence layer โ€” no consistency, no audit trail, no scale.
The Solution

One Platform. 12 Agents. Every Answer.

GenomixIQ replaces your fragmented toolchain with a single agentic AI platform that delivers clinical-grade results in minutes, not days.

โœ“
8-Second Variant Classification
From VCF submission to ACMG/AMP classification with VIS score, citations, and G-ARVIS quality attestation in under 8 seconds.
โœ“
Zero-Hallucination Clinical Reports
Every clinical statement cites a validated source. Our G-ARVIS Safety gate blocks any uncited pathogenic call โ€” guaranteed.
โœ“
End-to-End Autonomous Pipeline
From raw FASTQ/VCF to signed-out physician report โ€” QC, annotation, classification, PGx, somatic profiling, and trial matching in one flow.
The Molecular Agent Mesh

12 Agents. One Mission.

Each agent is a domain specialist โ€” trained on genomics knowledge, constrained by G-ARVIS quality gates, and self-correcting via ARGUS-AI. They collaborate autonomously, in real time.

LIVE
VariantClassifierAgent
ACMG/AMP 2015 standards. All evidence codes (PVS1โ€“BP7). Proprietary VIS Score across 8 evidence streams.
ACMG ยท VIS ยท ARGUS
LIVE
ClinicalAnnotatorAgent
Real-time lookups across ClinVar, gnomAD v4, OMIM, OncoKB, ClinGen. Contextualizes every variant against 7 knowledge bases.
ClinVar ยท gnomAD ยท OMIM
LIVE
ReportGeneratorAgent
Zero-hallucination physician-ready reports. Every claim cites a source. FHIR R4 DiagnosticReport + HL7 v2.5 ORU output.
FHIR ยท HL7 ยท Zero-Hallucination
LIVE
PharmacogenomicsAgent
CPIC-guided diplotyping for 300+ drug-gene pairs. CYP2D6, CYP2C19, DPYD, TPMT, HLA-B. FDA PGx labeling integrated.
CPIC ยท 300+ Drug-Gene
LIVE
SomaticTumorAgent
TMB, MSI-H/MSS detection. OncoKB Level 1โ€“4 therapy matching. Fusion detection. Immunotherapy recommendations.
TMB ยท MSI ยท OncoKB
LIVE
DrugDiscoveryAgent
Target validation from genetic associations. ADMET in-silico prediction. ChEMBL bioactivity mining. Competitor analysis.
ChEMBL ยท ADMET ยท Targets
LIVE
LiteratureMinerAgent
PubMed RAG over 2M genomics papers. Evidence grading Aโ€“D. ACMG PS3/BS3 functional evidence coding.
PubMed ยท RAG ยท Evidence
LIVE
ResearchCoordinatorAgent
Real-time NCT clinical trial matching. GWAS catalog associations. Drug repurposing candidates from genetic targets.
NCT ยท GWAS ยท Trials
LIVE
ProteinStructureAgent
AlphaFold3 integration for structural impact. ฮ”ฮ”G stability prediction. ACMG PP3/BP4 structural evidence generation.
AlphaFold3 ยท ฮ”ฮ”G
LIVE
PopulationGeneticsAgent
gnomAD v4 allele frequency contextualization. Founder variant detection. ACMG BA1/BS1/PM2 evidence coding.
gnomAD v4 ยท Ancestry
LIVE
FamilyStudiesAgent
Trio analysis and de novo detection (PS2/PM6). Segregation with LOD scoring. Cascade testing coordination.
Trio ยท De Novo ยท Pedigree
LIVE
QualityControlAgent
Coverage depth, contamination detection (VerifyBamID2), sex inference, ts/tv, batch outlier. Automated QC pass/fail.
QC ยท Contamination ยท Batch
Proprietary Quality Framework

G-ARVIS: The Industry's First AI Quality Standard for Genomics

Every AI output passes through 6 quality dimensions before reaching a clinician. This is not optional. It is enforced.

G
Groundedness
0.95
A
Accuracy
0.91
R
Reliability
0.93
V
Variance
0.03
I
Infer Cost
$0.0014
S
Safety
1.000

The Zero-Hallucination Guarantee

The Safety dimension enforces a hard binary rule: zero uncited pathogenic classifications. If an agent cannot back a Pathogenic call with a validated citation, the output is blocked and escalated to human review โ€” automatically.

When G-ARVIS fails, ARGUS-AI triggers an autonomous correction loop โ€” re-querying knowledge bases, injecting citations, and re-evaluating โ€” before any human escalation.

COMPOSITE SCORE ยท LIVE
0.937
G-ARVIS Composite ยท Threshold โ‰ฅ 0.88 ยท โœ“ All gates passing
Solutions

Built for Every Genomics Workflow

Hereditary Cancer โ€” Results in Hours, Not Days

๐Ÿงฌ
80+ Gene Panel Coverage
BRCA1/2, PALB2, ATM, CHEK2, Lynch syndrome (MLH1/MSH2/MSH6/PMS2), and all major hereditary cancer genes.
โšก
STAT Orders in 4 Hours
Urgent orders routed to Claude Opus with expedited G-ARVIS scoring. Full report to ordering physician in under 4 hours.
๐Ÿ“‹
Cascade Testing Coordination
Automatically identifies at-risk family members and generates cascade testing letters for genetic counselors.
// BRCA1 c.5266dupC โ€” GenomixIQ result
{
  "classification": "Pathogenic",
  "vis_score": 0.97,
  "acmg_criteria": ["PVS1", "PS4", "PM2"],
  "garvis_safety": 1.0,
  "citations": 8, // all verified
  "zero_hallucination": true,
  "latency_ms": 4230
}

Rare Disease โ€” Diagnose the Undiagnosed

๐Ÿ”ฌ
Trio & Whole Exome Analysis
De novo detection confirmed across proband + both parents. LOD scoring, HPO phenotype matching, RNA-Seq splicing.
๐Ÿงฉ
Cross-Omics Correlation
Correlates genomics, transcriptomics, proteomics, and metabolomics for multi-omics rare disease cases.
// De novo detection โ€” Trio analysis
{
  "de_novo_confirmed": true,
  "acmg_code": "PS2",
  "hpo_match_score": 0.92,
  "recurrence_risk": "<1%"
}

Pharmacogenomics โ€” Right Drug. Right Dose.

๐Ÿ’Š
300+ Drug-Gene Pairs
CPIC Level A/B for CYP2D6, CYP2C19, CYP2C9, DPYD, TPMT, UGT1A1, SLCO1B1, G6PD, HLA-B, and more.
๐ŸŽฏ
Actionable Dosing Guidance
Phenotype assignment with drug-specific recommendations citing FDA biomarker labeling and CPIC guidelines.
// CYP2D6 *4/*4 โ€” Poor Metabolizer
{
  "phenotype": "Poor Metabolizer",
  "codeine": "CONTRAINDICATED",
  "cpic_level": "A",
  "fda_label": true
}

Somatic Oncology โ€” Precision at Every Stage

๐ŸŽฏ
TMB & MSI Classification
FDA-threshold TMB-High โ‰ฅ10 mut/Mb. MSI-H/MSS determination. Pembrolizumab eligibility flagged automatically.
๐Ÿ’‰
OncoKB Therapy Matching
Level 1โ€“4 actionability. Approved targeted therapies, immunotherapy, and clinical trial matches.
// NSCLC Tumor Profile
{
  "tmb": 14.2, // High
  "msi_status": "MSI-H",
  "therapy": "Pembrolizumab",
  "oncokb_level": "1"
}

Drug Discovery โ€” From Genome to Lead Candidate

๐Ÿงช
Target Validation
AI mining of GWAS, rare variant burden, eQTL studies. Druggability scoring from PDB + ChEMBL data.
โš—๏ธ
ADMET Prediction
In-silico ADME and toxicity profiling. Lead scaffold suggestions with competitor analysis.
// KRAS G12C โ€” Drug Discovery
{
  "druggability": 0.87,
  "competitors": ["Sotorasib","Adagrasib"],
  "trial_matches": 14,
  "regulatory": "Breakthrough eligible"
}
Integrations

Connects to Everything You Already Use

๐Ÿฅ
Epic / SMART
๐Ÿจ
Cerner
๐Ÿงช
Illumina DRAGEN
โ˜๏ธ
AWS HealthLake
๐Ÿ”ต
Azure Health
๐ŸŸก
Google HCLS
๐Ÿ“Š
Snowflake
๐Ÿ—„๏ธ
Meditech
๐Ÿ”—
HL7 / FHIR
๐Ÿงฌ
ClinVar
๐ŸŒ
gnomAD v4
๐Ÿ“š
OMIM / HGMD
Why Trust GenomixIQ

Built for Partnership from Day One

GenomixIQ is launching now and actively seeking its first design partners. No fabricated logos, no invented testimonials โ€” a real platform, built by a practitioner with deep roots in production genomics and clinical AI, looking for the right partners to grow with.

AP
Anil S. Prasad
Founder, Ambharii Labs ยท One of 100 Most Influential AI Leaders USA 2024

28 years building production AI/ML platforms across genomics, healthcare, and enterprise โ€” from clinical lab data infrastructure to large-scale revenue cycle AI and enterprise energy platforms. GenomixIQ brings that practitioner depth into a first-of-its-kind agentic platform purpose-built for the genetics and precision medicine industry.

Top 100 AI Leader USA 2024 28 Years Production AI/ML Genomics ยท Healthcare ยท Enterprise Fortune 100 Track Record Clinical AI Community Leader
What We Can Prove Right Now โ€” Live on the Platform
VERIFIED ยท BRCA1 c.5266dupC
ClinVar 5-star Pathogenic variant classified correctly in 4.2 seconds with 8 verified citations. G-ARVIS composite: 0.971. Safety: 1.0.
LIVE API ยท TRY IT NOW
The entire API is publicly documented and testable at api.genomixiq.com/api/docs. Submit a real variant, get a real classification. No demo account needed.
OPEN SOURCE COMPONENTS
ARGUS-AI SDK published on PyPI as argus-ai. G-ARVIS evaluation utilities available on GitHub at github.com/anilatambharii.
๐Ÿ”ฌ
Be One of the First 10 Design Partners

We are selecting 10 clinical labs, health systems, or research institutions to shape the platform alongside us. Design partners get free access during development, co-authorship on validation studies, and preferred pricing at launch.

Apply for Design Partner Access
Pricing

Simple, Transparent Pricing

All plans include HIPAA BAA, 99.95% uptime SLA, and full API access.

Starter
$2,500/mo
Up to 500 tests/month. Ideal for independent labs entering genomics.
โœ“ Core variant classification
โœ“ Standard hereditary panels
โœ“ FHIR R4 reports
โœ“ G-ARVIS quality scoring
โœ“ Email support
Get Started
Most Popular
Professional
$8,500/mo
Up to 5,000 tests/month. All 12 agents. PGx, somatic, research, trial matching.
โœ“ All 12 autonomous agents
โœ“ Pharmacogenomics module
โœ“ Somatic tumor profiling
โœ“ Clinical trial matching
โœ“ Priority support + SLA
Start Free Trial
Enterprise
Custom
Unlimited tests. Private cloud or on-premises. Dedicated infrastructure and SLAs.
โœ“ Unlimited test volume
โœ“ On-prem deployment option
โœ“ Custom model fine-tuning
โœ“ Dedicated support engineer
โœ“ SOC2 Type II + audit logs
Contact Us
Research
Custom
Academic and research institutions. Cohort tools, GWAS, population analytics.
โœ“ De-identified analytics
โœ“ GWAS + PheWAS tools
โœ“ Drug repurposing engine
โœ“ IRB data management
โœ“ Academic pricing
Apply Now
Partnerships

Partner With Us

Actively building strategic partnerships across the genomics and health tech ecosystem.

๐Ÿฅ Clinical Integration
Health Systems & Hospital Networks
Embed GenomixIQ into your genomics service line. Co-branded reports, Epic integration, and revenue-share on expanded test volume.
Become a Clinical Partner โ†’
๐Ÿงฌ Technology
Sequencing & Instrument Manufacturers
Integrate GenomixIQ directly into your instrument software or cloud portal. Illumina, PacBio, Oxford Nanopore partnerships welcome.
Technology Partner Inquiry โ†’
๐Ÿ’Š Pharma & Biotech
Pharmaceutical & Biotech Companies
Power your companion diagnostic development and drug discovery programs with GenomixIQ's agentic research intelligence layer.
Pharma Partnership Inquiry โ†’
โ˜๏ธ Cloud & Infrastructure
Cloud Providers & Marketplace
Available on AWS, Azure, and GCP Marketplaces. Co-sell program with major cloud providers for health and life sciences verticals.
Cloud Partner Program โ†’
๐ŸŽ“ Academic & Research
Academic Medical Centers
NIH-funded research, IRB-approved studies, and grant-supported genomics programs. Co-publication and validation study partnerships.
Research Collaboration โ†’
๐Ÿค Resellers
Health IT Consultants & Integrators
Join the GenomixIQ reseller network. Certified partner training, deal registration, and competitive margins.
Join Reseller Network โ†’
For Investors & Acquirers

A Category-Defining Asset in the $28B Genomics Market

GenomixIQ is the only platform combining agentic AI, proprietary quality frameworks (G-ARVIS, VIS), zero-hallucination clinical outputs, and multi-cloud deployment โ€” in a HIPAA-compliant, acquisition-ready architecture.

๐Ÿ“Š TAM: $28B genomics + $8B precision medicine software
๐Ÿ† VIS Algorithm + MAM Topology โ€” Patent Pending (USPTO)
๐Ÿ”’ Trade Secret: G-ARVIS weights, ARGUS correction protocol
โ˜๏ธ Any-cloud, any-prem โ€” zero vendor lock-in
โšก Built by: Top 100 AI Leader USA 2024 โ€” Anil S. Prasad
Request Investment Deck โ†’

Strategic Acquirer Landscape

Illumina
HIGHEST FIT
Instrument + software vertical integration
$500Mโ€“$2B
Roche / FMI
HIGHEST FIT
Clinical genomics pipeline replacement
$600Mโ€“$2B
Microsoft
HIGH FIT
Azure Health AI product line
$300Mโ€“$1B
NVIDIA
HIGH FIT
BioNeMo genomics AI showcase
$400Mโ€“$1.5B
Epic Systems
HIGH FIT
EHR-native genomics module
$250Mโ€“$800M
Snowflake
STRONG FIT
Genomics Data Cloud product
$200Mโ€“$600M
๐Ÿš€ Now Accepting Design Partners

Ready to Transform Your
Genomics Program?

Demo requests, partnership inquiries, investment conversations โ€” one person, one email.

All Inquiries โ€” Anil Responds Personally
anil@ambharii.com

Founder, Ambharii Labs ยท One of 100 Most Influential AI Leaders USA 2024

๐Ÿ”ฌ Demo Classify a variant live
๐Ÿค Partners Clinical & tech partnerships
๐Ÿ’ผ Investors Acquisition conversations
๐Ÿ“‹ API Developer access
Schedule Live Demo Connect on LinkedIn โ†’